Systematic review on effectiveness and safety of pharmacologic treatment of persisting pain in children
WHO
Systematic review on effectiveness and safety of pharmacologic treatment of persisting pain in children
Request for proposal
Reference:
2019/ULC/MCA/0001
Beneficiary countries:
Switzerland
Published on:
03-Sep-2019
Deadline on:
28-Sep-2019 17:00 (GMT 2.00)
Description
18 September 2019: the closing date for submission of proposals is postponed to 28 September 2019 (previously 23 September).
WHO requires the successful bidder to carry out a systematic review on the effectiveness and safety of pharmacologic management of persisting pain in children, including evidence from non-randomized trials, observational studies and indirect evidence.
See attached detailed Terms of Reference for complete information.
Ayesha de Costa - deay@who.int, Tel: +41 000
Email:
deay@who.int
First name:
Ayesha
Surname:
de Costa
Telephone country code:
Switzerland (+41)
Telephone number:
000
Pura Rayco-Solon - raycosolonp@who.int, Tel: +41 000
Email:
raycosolonp@who.int
First name:
Pura
Surname:
Rayco-Solon
Telephone country code:
Switzerland (+41)
Telephone number:
000
51271613
-
Lidocaine
51271622
-
Bupivacaine hydrochloride
51271623
-
Bupivacaine hydrochloride monohydrate
51271629
-
Lidocaine hydrochloride
51271636
-
Ropivacaine hydrochloride monohydrate
51272006
-
Thiopental sodium
51272111
-
Amethocaine or tetracaine
51272207
-
Ketamine hydrochloride
51272302
-
Etomidate
51272401
-
Desflurane
51272406
-
Isoflurane
51272408
-
Sevoflurane
51272901
-
Propofol
51273009
-
Remifentanil
51273921
-
Bupivacaine/dextrose
51273937
-
Epinephrine/lidocaine
51273950
-
Felypressin/prilocaine
85101701
-
Health policy
85101705
-
Public health administration
85111617
-
Drug addiction prevention or control services
93131702
-
Sanitation programs
93131703
-
Research programs
93131704
-
Disease prevention or control services
93131705
-
Drug abuse prevention or control programs